225Ac Prostate-Specific Membrane Antigen Posttherapy α Imaging: Comparing 2 and 3 Photopeaks

Affiliations


Abstract

Ac-based PSMA-targeted therapy has emerged as promising agent for the treatment of metastatic castration-resistant prostate cancer. Posttherapy image is used for tracer localization and dosimetry. Prior 2 photopeaks of 440 and 218 KeV were reported for posttherapy imaging. Our study of gamma ray spectrum, phantom, and clinical images show that imaging with 3 major photopeaks of 78, 218, and 440 KeV gives better quality images, high count statistics, and higher number of lesion delineations. It is therefore suggested that posttherapy imaging may be carried out using 3 major abundant photopeaks.


Similar articles

225Ac-PSMA-617 Radioligand Posttherapy Imaging in Metastatic Castrate-Resistant Prostate Cancer Patient Using 3 Photopeaks.

Vatsa R, Sood A, Vadi SK, Das CK, Kaur K, Parmar M, Mittal BR.Clin Nucl Med. 2020 Jun;45(6):437-438. doi: 10.1097/RLU.0000000000003031.PMID: 32366786

Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions.

Okamoto S, Thieme A, Allmann J, D'Alessandria C, Maurer T, Retz M, Tauber R, Heck MM, Wester HJ, Tamaki N, Fendler WP, Herrmann K, Pfob CH, Scheidhauer K, Schwaiger M, Ziegler S, Eiber M.J Nucl Med. 2017 Mar;58(3):445-450. doi: 10.2967/jnumed.116.178483. Epub 2016 Sep 22.PMID: 27660138

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control.

Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, Morgenstern A.J Nucl Med. 2018 May;59(5):795-802. doi: 10.2967/jnumed.117.203539. Epub 2018 Jan 11.PMID: 29326358

[PSMA-targeted radioligand therapy in prostate cancer].

Heck MM, Retz M, Tauber R, Knorr K, Kratochwil C, Eiber M.Urologe A. 2017 Jan;56(1):32-39. doi: 10.1007/s00120-016-0274-3.PMID: 27885457 Review. German.

The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.

Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, Haberkorn U.J Nucl Med. 2016 Oct;57(Suppl 3):79S-89S. doi: 10.2967/jnumed.115.170720.PMID: 27694178 Review.


Cited by

Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging.

Delker A, Schleske M, Liubchenko G, Berg I, Zacherl MJ, Brendel M, Gildehaus FJ, Rumiantcev M, Resch S, Hürkamp K, Wenter V, Unterrainer LM, Bartenstein P, Ziegler SI, Beyer L, Böning G.Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1280-1290. doi: 10.1007/s00259-022-06092-1. Epub 2023 Jan 11.PMID: 36629878 Free PMC article.

Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?

Pallares RM, Abergel RJ.Front Med (Lausanne). 2022 Dec 22;9:1020188. doi: 10.3389/fmed.2022.1020188. eCollection 2022.PMID: 36619636 Free PMC article. Review.

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists.

Shi M, Jakobsson V, Greifenstein L, Khong PL, Chen X, Baum RP, Zhang J.Front Med (Lausanne). 2022 Dec 7;9:1034315. doi: 10.3389/fmed.2022.1034315. eCollection 2022.PMID: 36569154 Free PMC article. Review.

Compton and proximity imaging of 225Ac in vivo with a CZT gamma camera: a proof of principle with simulations.

Caravaca J, Huh Y, Gullberg GT, Seo Y.IEEE Trans Radiat Plasma Med Sci. 2022 Nov;6(8):904-915. doi: 10.1109/trpms.2022.3166116. Epub 2022 Apr 11.PMID: 36338821

Radionuclides for Targeted Therapy: Physical Properties.

Stokke C, Kvassheim M, Blakkisrud J.Molecules. 2022 Aug 25;27(17):5429. doi: 10.3390/molecules27175429.PMID: 36080198 Free PMC article. Review.


KMEL References